Rezubio Pharmaceuticals advanced RZ-520 for chronic respiratory diseases into Phase I after IND clearances from the FDA and China’s NMPA. The program is moving into dosing for a Phase I trial in healthy volunteers, marking the start of clinical evaluation for the company’s respiratory lead asset.